Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC5R | P33032 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19002826 | 0.86 | OPRM1 (0.50) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL19002822 | 0.85 | OPRM1 (0.69) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL19049620 | 0.82 | OPRM1 (0.57) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL18997815 | 0.81 | SLC6A2 (0.55) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL24943172 | 0.79 | OPRM1 (0.51) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL21900761 | 0.78 | OPRM1 (0.53) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL6207029 | 0.71 | C5AR1 (0.47) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL12005633 | 0.71 | OPRM1 (0.56) | OPRM1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14099804 | 0.70 | C5AR1 (0.46) | OPRM1ALDH1A1THRBLMNAMEN1 | |
| SCHEMBL6206609 | 0.70 | C5AR1 (0.46) | OPRM1ALDH1A1THRBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | OPRM1 3991/4885ALDH1A1 2861/4885THRB 1817/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | OPRM1 3875/4885ALDH1A1 2765/4885THRB 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.